November 2025 in “Toxicology Communications” The study observed that topical minoxidil poses an increasing and potentially deadly risk to pets, particularly cats, highlighting the urgent need for better public education and product labeling.
2 citations
,
May 1985 in “Environmental Health Perspectives” This report examines the mechanisms by which TCDD affects human epidermal and carcinoma cells, aiming to create a risk assessment model for halogenated aromatic compounds, but presents no new clinical results.
28 citations
,
January 2017 in “Critical Reviews in Therapeutic Drug Carrier Systems” This review classifies engineered nanomaterials by composition and application in biomedicine, highlighting diverse uses like regenerative medicine and potential occupational side effects, but reports no new clinical results.
3 citations
,
March 2017 in “Regulatory toxicology and pharmacology” In this study, aleglitazar and its metabolite M6 were evaluated for safety in non-clinical settings, revealing organ-targeting effects common to PPAR agonists but no significant tumor increase in rat carcinogenicity studies, supporting progression to Phase 3 clinical trials.
June 2026 in “Frontiers in Medicine” This study conducted a large-scale comparison using FAERS data to assess the post-marketing safety profiles of spironolactone, eplerenone, and finerenone, finding unique adverse event patterns for each drug and highlighting the need for personalized safety monitoring and further investigation in other pharmacovigilance databases.